Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Solventum Corporation (SOLV)

Solventum Corporation (SOLV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,881,041
  • Shares Outstanding, K 173,448
  • Annual Sales, $ 8,254 M
  • Annual Income, $ 478,000 K
  • EBIT $ 2,192 M
  • EBITDA $ 2,747 M
  • 60-Month Beta 0.34
  • Price/Sales 1.67
  • Price/Cash Flow 8.62
  • Price/Book 2.98

Options Overview Details

View History
  • Implied Volatility 26.66% (+2.80%)
  • Historical Volatility 29.10%
  • IV Percentile 13%
  • IV Rank 14.29%
  • IV High 62.22% on 04/10/25
  • IV Low 20.73% on 12/26/25
  • Expected Move (DTE 2) 1.66 (2.07%)
  • Put/Call Vol Ratio 0.07
  • Today's Volume 114
  • Volume Avg (30-Day) 247
  • Put/Call OI Ratio 0.30
  • Today's Open Interest 7,785
  • Open Int (30-Day) 8,381
  • Expected Range 78.32 to 81.64

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 1.50
  • Number of Estimates 5
  • High Estimate 1.51
  • Low Estimate 1.49
  • Prior Year 1.41
  • Growth Rate Est. (year over year) +6.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
78.18 +2.42%
on 01/05/26
86.36 -7.27%
on 01/09/26
-2.90 (-3.49%)
since 12/12/25
3-Month
66.11 +21.13%
on 11/06/25
88.20 -9.21%
on 12/02/25
+8.59 (+12.02%)
since 10/14/25
52-Week
60.70 +31.93%
on 04/09/25
88.20 -9.21%
on 12/02/25
+9.89 (+14.09%)
since 01/14/25

Most Recent Stories

More News
3 Reasons SOLV is Risky and 1 Stock to Buy Instead

3 Reasons SOLV is Risky and 1 Stock to Buy Instead

SOLV : 80.19 (+0.20%)
Solventum Completes Acquisition of Acera Surgical

ST. PAUL, Minn. , Dec. 23, 2025 /PRNewswire/ -- Solventum  (NYSE: SOLV) announced today it has completed the acquisition of Acera Surgical (Acera), a privately held bioscience company...

SOLV : 80.19 (+0.20%)
Global Expert Panel Publishes New Recommendations on Advanced Use of Closed Incision Negative Pressure Therapy

New guidance highlights evolving surgical procedure applications of reticulated open cell foam (ROCF) dressings to support patient safety, surgical outcomes and future standards of care

SOLV : 80.19 (+0.20%)
Solventum Earns Diamond Level HIRC Resiliency Badge, Demonstrating Best-In-Class Supply Chain Strength

ST. PAUL, Minn. , Dec. 16, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today that it has achieved the Diamond Level Resiliency Badge from the Healthcare Industry Resilience Collaborative...

SOLV : 80.19 (+0.20%)
Is Solventum Stock Outperforming the Nasdaq?

Solventum has delivered stronger performance than the Nasdaq Composite over the past year, reinforcing analysts’ moderate optimism regarding the stock’s forward outlook.

SOLV : 80.19 (+0.20%)
$NASX : 23,384.30 (-1.37%)
BDX : 206.97 (+2.70%)
3 Value Stocks with Open Questions

3 Value Stocks with Open Questions

SOLV : 80.19 (+0.20%)
CAG : 17.12 (+3.32%)
MAN : 30.37 (+2.57%)
1 Mid-Cap Stock on Our Buy List and 2 We Question

1 Mid-Cap Stock on Our Buy List and 2 We Question

SOLV : 80.19 (+0.20%)
AVY : 188.35 (+0.33%)
NXT : 95.98 (-4.25%)
1 Unpopular Stock That Should Get More Attention and 2 We Ignore

1 Unpopular Stock That Should Get More Attention and 2 We Ignore

SOLV : 80.19 (+0.20%)
CL : 84.39 (+1.72%)
IVZ : 28.30 (-0.21%)
Up Over 20% in 2025, These 3 Stocks Are Boosting Buyback Capacity

Check out these three stocks that are up more than 20% in 2025 and just increased their buyback capacity. One stock experiencing strong growth stands out.

SOLV : 80.19 (+0.20%)
SE : 125.25 (-3.55%)
AVGO : 337.74 (-4.76%)
KEYS : 209.04 (-0.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Solventum is an independent healthcare company. Its business segment includes Medical Surgical, Dental Solutions, Health Information Systems and Purification and Filtration. Solventum is based in ST. PAUL, Minn.

See More

Key Turning Points

3rd Resistance Point 89.66
2nd Resistance Point 87.56
1st Resistance Point 83.80
Last Price 80.19
1st Support Level 77.93
2nd Support Level 75.83
3rd Support Level 72.07

See More

52-Week High 88.20
Last Price 80.19
Fibonacci 61.8% 77.69
Fibonacci 50% 74.45
Fibonacci 38.2% 71.20
52-Week Low 60.70

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar